Login / Signup

Retrospective review of patients with myasthenia gravis switched from plasma exchange therapy to efgartigimod treatment.

Anahit MehrabyanRebecca E Traub
Published in: Muscle & nerve (2024)
In this series, efgartigimod appeared effective and well tolerated in patients switched from TPE.
Keyphrases
  • myasthenia gravis
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • patient reported outcomes
  • replacement therapy